Nurexone Biologic Inc. (NRX.V)
Market Activity – 24‑hour Period Ending 04:00 PM Central Europe, Friday 23 Oct 2026
- Trading performance: flat (0 %).
- Current price: CAD 0.53.
- Shares outstanding: 96.4 million.
- Market capitalization: CAD 38.2 million.
- 24‑hour trading volume: approximately CAD 9.2 k.
- Price change since the previous month‑end: –15.62 %.
- 200‑day simple moving average: CAD 0.60.
- 52‑week high: CAD 0.76 (24 Nov 2025).
- 52‑week low: CAD 0.44 (5 Aug 2026).
Recent Corporate Development
NurExone Biologic Inc. announced that a recent production run has successfully doubled exosome output. Two bioreactors were operated in parallel, while overall manufacturing time remained unchanged. The parallel process maintained the same quality characteristics and critical product attributes as single‑reactor runs, indicating that the modular scaling strategy can increase yields without compromising consistency.
This milestone supports the company’s plan to expand production capacity through standardized, parallel units rather than larger vessels. The strategy aims to protect capital, shorten development timelines, and meet growing commercial demand.
Key elements of the approach include:
- U.S. subsidiary Exo‑Top and partnership with Made Scientific.
- Supply of the lead therapeutic candidate and potential business‑to‑business exosome products.
Comparative Performance of Peer Stocks – 24 Hours
| Stock | 24‑hour movement | Current price | Market capitalization |
|---|---|---|---|
| Sterling Metals (SAG.V) | –2.27 % | CAD 0.86 | CAD 44.2 million |
| Global Receivables Management (EPF.V) | 0 % | CAD 0.32 | CAD 44.5 million |
| Jericho Energy Ventures (JEV.V) | +8.33 % | CAD 0.20 | CAD 44.4 million |
| Electra Battery Materials (ELBM.V) | +1.79 % | CAD 0.58 | CAD 44 million |
Jericho Energy Ventures has revised its investor‑relations agreement with Orange Group Advisors, removing a previously agreed cash finder’s fee tied to future financings. The amendment retains standard cash fees and expense reimbursements, with no new securities issued to the advisor. The company remains focused on integrating energy infrastructure with artificial‑intelligence data‑center development.
Company Profile
NurExone Biologic Inc. is headquartered in Calgary, Canada. The company develops novel biologic and minimally invasive treatments for spinal cord injury and traumatic brain injury. It operates globally and is listed on the TSX Venture Exchange. Additional information is available on the company’s website: www.nurexone.com .
